Pilot Launch You have early access to the Barinhall Compliance Intelligence Portal. Coverage and features are expanding weekly. Share feedback →
← Back to Feed
View source document ↗
T4 SEC Medium Confidence Proposed Rule

SEC Proposes Amendments to Exchange Act Rule 15c2-11

Regulatory clarification to limit Rule 15c2-11 scope to equity securities only

LOW
Impact Level
Top: compliance (2)

Classification

Regulatory Program
Exchange Act Rule 15c2-11
Doc Type
Proposed Rule
Effective Date
Days to Action
Comment Deadline
Published

Urgency Basis

Proposed rule with 60-day comment period - no immediate implementation timeline specified

Operational Context

Flags
Legal Review Required
Affected Functions
Trading Compliance Legal
Institution Applicability
Broker-Dealers Otc Market Makers Securities Firms With Otc Quotation Activities

Impact by Category

Compliance
2
Operational
1
Data Governance
1
Model Risk
0
Reporting & Disclosure
2
Capital & Liquidity
0
Consumer Protection
1
Third-Party Risk
1

Key Requirements

- Review current OTC quotation practices for compliance with equity securities focus - Ensure quotation activities align with clarified Rule 15c2-11 scope - Assess information gathering procedures for equity securities quotations - Submit comments during 60-day comment period if impacts identified

Scoring Rationale

Low impact clarifying amendment that narrows existing rule scope rather than expanding requirements. Primarily affects broker-dealers engaged in OTC quotation activities. No new substantive compliance burdens anticipated.

Scored: 2026-06-03T18:03:13.482Z Model: claude-sonnet-4-20250514 Confidence: Medium Aggregate Score: 1.1
AI Analysis Disclosure — This record, including its scores, impact assessments, and Advisory Assessment (impact, risk, and recommended actions), was generated by an AI model and may contain errors or omissions. The Advisory Assessment is a starting point for analysis, not a substitute for professional judgment. Effective dates, applicability determinations, impact assessments, and any recommended actions should be independently verified against primary regulatory source documents and reviewed by qualified compliance or legal personnel before taking compliance action. This output does not constitute legal or compliance advice.